RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
New Horizon Health of Hangzhou completed a $66 million C round of financing that was led by VMS Group and included Legend Capital and Softbank China. Founded in 2013, New Horizon develops products that detect and screen for early stage cancers. So far, the company has launched diagnostic tests for intestinal and lung cancer. The C round brings New Horizon’s total funding to over $100 million. New Health’s $20 million A round was led by Qiming Venture with Legend Capital and Soft Bank also participating.
Source: China Biotoday
